Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014;171:309–25.CrossrefWeb of SciencePubMedGoogle Scholar
Pang J, Lansberg PJ, Watts GF. International developments in the care of familial hypercholesterolemia: where now and where to next? J Atheroscler Thromb 2016;23:505–19.Web of SciencePubMedCrossrefGoogle Scholar
Tatishcheva YA, Mandelshtam MY, Golubkov VI, Lipovetsky BM, Gaitskhoki VS. Four new mutations and two polymorphic variants of the low-density lipoprotein receptor gene in familial hypercholesterolemia patients from St. Petersburg. Genetika 2001;37:1082–6.Google Scholar
Chmara M, Wasag B, Zuk M, Kubalska J, Wegrzyn A, Bednarska-Makaruk M, et al. Molecular characterization of Polish patients with familial hypercholesterolemia: novel and recurrent LDLR mutations. J Appl Genet 2010;51:95–106.PubMedCrossrefWeb of ScienceGoogle Scholar
Defesche JC, Schurrman EJ, Klaaijsen LN, Khoo KL, Wiegman A, Stalenhoef AF. Silent exonic mutations in the low-density lipoprotein receptor gene that cause familial hypercholesterolemia by affecting mRNA splicing. Clin Genet 2008;73:573–8.Web of SciencePubMedCrossrefGoogle Scholar
Boright AP, Conelly PW, Brunt JH, Morgan K, Hegele HA. Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. J Hum Genet 1998;43:153–9.PubMedCrossrefGoogle Scholar
Huijgen R, Kindt I, Defesche JC, Kaastelein JP. Cardiovascular risk in relation to functionality of sequence variants in the gene coding for the low-density lipoprotein receptor: a study among 29 365 individuals tested for 64 specific low-density lipoprotein-receptor sequence variants. Eur Heart J 2012;33:2325–30.CrossrefWeb of SciencePubMedGoogle Scholar
Huijgen R, Hutten BA, Kindt I, Vissers MN, Kastelein JP. Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia a cross-sectional study in 26 406 individuals tested for genetic FH. Circ Cardiovasc Genet 2012;5:354–9.PubMedCrossrefGoogle Scholar
Sjouke B, Defesche JC, Hartgers ML, Wiegman A, Roeters van Lennep JE, Kastelein JJ. Double-heterozygous autosomal dominant hypercholesterolemia: clinical characterization of an underreported disease. J Clin Lipidol 2016;10:1462–9.CrossrefPubMedWeb of ScienceGoogle Scholar
Hartgers ML, Defesche JC, Langslet G, Hopkins PN, Kastelein JJ, Baccara-Dinet MT. Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemia. J Clin Lipidol 2018;12:390–6.PubMedCrossrefWeb of ScienceGoogle Scholar
Jannes CE, Santos RD, Silva PR, Turolla L, Gagliardi AC, Marsiglia JD, et al. Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects. Atherosclerosis 2015;238:101–7.CrossrefPubMedWeb of ScienceGoogle Scholar
Molfetta GA, Zanette DL, Santos JE, Silva WA. Mutational screening in the LDLR gene among patients presenting familial hypercholesterolemia in the southeast of Brazil. Genet Mol Res 2017;16:gmr16039226.Web of ScienceGoogle Scholar
Mehta R, Zubirán R, Martagón AJ, Vazquez-Cárdenas A, Segura-Kato Y, Tusié-Luna MT, et al. The panorama of familial hypercholesterolemia in Latin America: a systematic review. J Lipid Res 2016;57:2115–29.Web of ScienceCrossrefPubMedGoogle Scholar
About the article
Published Online: 2018-07-17
Published in Print: 2018-12-19
Author contributions: All authors were involved in protocol development, Institutional Review Board approval and patient recruitment. HPC conceived and carried out experiments, analyzed data and wrote the paper. EC helped with sample and data collections and molecular analysis. MVO helped with sample and data collections and molecular analysis. TCMS supervised molecular analysis. ICB conceived the study and supervised patient recruitment. ELS conceived the study, supervised experiments and data analyses and wrote the paper. All authors reviewed and edited the manuscript and approved the definitive version of the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.